Metabolic & Weight Management

Incretin mimetics, GLP-1 agonists, and weight reduction compounds designed to study metabolic control pathways.

Compounds in this category

• Retatrutide (Reta)

  Next-generation triple receptor agonist (GLP-1, GIP, GCGR) driving advanced metabolic homeostasis.

  C223H343N61O67S · 4731.3 g/mol · 99.40% assay

• Tirzepatide (Tirze)

  Dual GIP and GLP-1 receptor agonist targeting glucose homeostasis and body composition dynamics.

  C225H348N48O68 · 4813.5 g/mol · 99.65% assay

• Semaglutide

  Established GLP-1 receptor agonist mimicking natural incretin hormones with modified clearance curves.

  C187H291N45O59 · 4113.6 g/mol · 99.50% assay

• Liraglutide

  Acylated human glucagon-like peptide-1 analog designed for clinical metabolic investigation models.

  C172H265N43O51 · 3751.2 g/mol · 99.30% assay

• Cagrilintide

  Long-acting amylin analogue targeting dual pathways in conjunction with incretin receptor systems.

  C145H225N41O45 · 3251.7 g/mol · 99.25% assay

• Mazdutide

  Novel dual GLP-1R/GCGR agonist targeting lipid elimination and cellular thermodynamic burn.

  C218H332N54O66 · 4610.1 g/mol · 99.45% assay

• Orforglipron

  Non-peptide oral small-molecule GLP-1 receptor agonist engineered for high bio-availability trials.

  C45H52F3N7O7 · 882.9 g/mol · 99.10% assay

• Gipreximutide

  Investigational selective GIP peptide derivative for glucose stabilization research studies.

  C198H312N50O58 · 4212.8 g/mol · 99.35% assay

• Tesofensine Conjugate

  Triple monoamine reuptake inhibitor conjugate researched for indirect metabolic optimization.

  C22H32Cl2N2O · 411.4 g/mol · 99.05% assay

• AOD9604

  Targeted fragment of human growth hormone (hGH 177-191) retaining specific lipolytic activity.

  C78H123N23O23S2 · 1817.1 g/mol · 99.60% assay

• HGH Fragment 176-191

  Truncated dynamic fragment of growth hormone tailored for adipose analysis in obesity models.

  C72H117N21O22S2 · 1716.9 g/mol · 99.55% assay

• CJC-1295 with DAC

  Long-acting GHRH analogue conjugated with Drug Affinity Complex to extend plasma presence.

  C165H271N43O48 · 3649.2 g/mol · 99.40% assay

• Ipamorelin

  Highly selective pentapeptide ghrelin receptor agonist stimulating growth hormone output.

  C38H49N9O5 · 711.9 g/mol · 99.80% assay

• Tesamorelin

  Synthetic growth hormone releasing hormone variant evaluated for abdominal adipose reduction.

  C221H366N72O67S · 5135.9 g/mol · 99.38% assay

• Sermorelin

  29-amino acid GHRH active core segment designed for simple cellular growth stimulation.

  C149H246N44O42S · 3357.9 g/mol · 99.70% assay